Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in Net LoansChange in TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Abvc Biopharma (ABVC) Cash from Operations (2018 - 2025)

Abvc Biopharma (ABVC) has disclosed Cash from Operations for 12 consecutive years, with 587582.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Cash from Operations rose 16.31% year-over-year to 587582.0, compared with a TTM value of 2986299.0 through Dec 2025, down 65.07%, and an annual FY2025 reading of 2986299.0, down 65.07% over the prior year.
  • Cash from Operations was 587582.0 for Q4 2025 at Abvc Biopharma, up from 964710.0 in the prior quarter.
  • Across five years, Cash from Operations topped out at 60230.0 in Q3 2024 and bottomed at 3429361.0 in Q2 2022.
  • Average Cash from Operations over 5 years is 1198920.1, with a median of 927821.5 recorded in 2023.
  • The sharpest move saw Cash from Operations surged 104.43% in 2024, then crashed 1701.71% in 2025.
  • Year by year, Cash from Operations stood at 2524616.0 in 2021, then surged by 81.74% to 461069.0 in 2022, then grew by 6.64% to 430463.0 in 2023, then tumbled by 63.11% to 702134.0 in 2024, then rose by 16.31% to 587582.0 in 2025.
  • Business Quant data shows Cash from Operations for ABVC at 587582.0 in Q4 2025, 964710.0 in Q3 2025, and 894174.0 in Q2 2025.